JPH0265865A - Medical or dental curable composition - Google Patents
Medical or dental curable compositionInfo
- Publication number
- JPH0265865A JPH0265865A JP63218066A JP21806688A JPH0265865A JP H0265865 A JPH0265865 A JP H0265865A JP 63218066 A JP63218066 A JP 63218066A JP 21806688 A JP21806688 A JP 21806688A JP H0265865 A JPH0265865 A JP H0265865A
- Authority
- JP
- Japan
- Prior art keywords
- powder
- aqueous solution
- curable composition
- curing liquid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 35
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 claims abstract description 16
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000005695 Ammonium acetate Substances 0.000 claims abstract description 7
- 229940043376 ammonium acetate Drugs 0.000 claims abstract description 7
- 235000019257 ammonium acetate Nutrition 0.000 claims abstract description 7
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 claims abstract description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 5
- 239000005696 Diammonium phosphate Substances 0.000 claims abstract 4
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910000388 diammonium phosphate Inorganic materials 0.000 claims abstract 4
- 235000019838 diammonium phosphate Nutrition 0.000 claims abstract 4
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims abstract 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 claims 1
- 238000004898 kneading Methods 0.000 abstract description 3
- 229920001515 polyalkylene glycol Polymers 0.000 abstract description 2
- 206010022998 Irritability Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002631 root canal filling material Substances 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 3
- ZRIUUUJAJJNDSS-UHFFFAOYSA-N ammonium phosphates Chemical compound [NH4+].[NH4+].[NH4+].[O-]P([O-])([O-])=O ZRIUUUJAJJNDSS-UHFFFAOYSA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- -1 sulfur hydrogen tartrate Chemical compound 0.000 description 2
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 229940036348 bismuth carbonate Drugs 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940023487 dental product Drugs 0.000 description 1
- GMZOPRQQINFLPQ-UHFFFAOYSA-H dibismuth;tricarbonate Chemical compound [Bi+3].[Bi+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GMZOPRQQINFLPQ-UHFFFAOYSA-H 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は医科用または歯科用硬化性組成物、特に覆軍材
や根管充填材等の歯髄に直接的に接触させて使用する材
料として好適な硬化性組成物に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention is applicable to medical or dental curable compositions, particularly as materials used in direct contact with dental pulp, such as covering materials and root canal filling materials. The present invention relates to suitable curable compositions.
〔従来の技術及びその解決すべき課題〕医科用または歯
科用硬化性組成物として生体適合性を有するα−リン酸
三カルシウムを粉剤として使用したものが注目されてき
ており、この種の硬化性組成物には、硬化液としてポリ
アクリル酸、クエン酸、酒石酸等の酸の水溶液が主とし
て使用されている。[Prior art and problems to be solved] A curable composition for medical or dental use that uses biocompatible α-tricalcium phosphate as a powder has been attracting attention. In the composition, an aqueous solution of an acid such as polyacrylic acid, citric acid, or tartaric acid is mainly used as a curing liquid.
しかしながら、これら酸水溶液を硬化液に使用すると硬
化性組成物のｐＨが低くなるため生体に対する刺激性を
有しているという問題点があった。However, when these acid aqueous solutions are used as a curing liquid, the pH of the curable composition becomes low, which poses a problem in that it is irritating to living organisms.
それ故、歯髄に直接的に接触して使用する覆軍材、根管
充填材等の材料として使用するには問題があった。Therefore, there are problems in using it as a material for covering materials, root canal filling materials, etc. that are used in direct contact with the dental pulp.
また、硬化液のｐＨの問題を解決するために、前記ポリ
アクリル酸、クエン酸、酒石酸等の酸に中性となる塩な
どを添加したものも開発されてきているが、このような
硬化液を使用した硬化性組成物は、崩壊率が高いという
問題点があった。In addition, in order to solve the problem of the pH of the curing liquid, products in which neutral salts are added to acids such as polyacrylic acid, citric acid, and tartaric acid have been developed. The curable composition using the above had a problem of high disintegration rate.
本発明者等はこのような現状に鑑み、前記問題点を解消
すべく、鋭意検討した結果、生体適合性を有し、かつ生
体に対し刺激性がなく、また崩壊率の低い医科用または
歯科用硬化性組成物を見出し本発明に到ったものである
。In view of the current situation, the inventors of the present invention have made extensive studies to solve the above problems, and have found a medical or dental product that is biocompatible, non-irritating to living organisms, and has a low disintegration rate. The present invention was achieved by discovering a curable composition for use in the present invention.
すなわち、本発明は、
α−リン酸三カルシウム粉末からなる粉剤と硬化液とか
らなる組成物において、前記硬化液がリン酸三アンモニ
ウム、蓚酸アンモニウム、酢酸アンモニウム及び酒石酸
水素す） ＩＪウムからなる群から選ばれた少なくとも
一種の塩の水溶液であることを特徴とする医科用または
歯科用硬化性組成物に関するものである。That is, the present invention provides a composition comprising a powder made of α-tricalcium phosphate powder and a hardening liquid, wherein the hardening liquid comprises a group consisting of triammonium phosphate, ammonium oxalate, ammonium acetate, and hydrogen tartrate. The present invention relates to a medical or dental curable composition, which is an aqueous solution of at least one salt selected from the following.
また、本発明はＸ線造影性が必要な場合、α−リン酸三
カルシウム粉末１００重量部及びヨードホルム粉末５〜
３０重量部からなる粉剤を使用した前記医科用または歯
科用硬化性組成物に関するものである。In addition, in the present invention, when X-ray contrast properties are required, 100 parts by weight of α-tricalcium phosphate powder and 5 to 5 parts of iodoform powder are used.
The present invention relates to the medical or dental curable composition using a powder containing 30 parts by weight.
以下、本発明の詳細な説明する。The present invention will be explained in detail below.
本発明の硬化性組成物を構成する粉剤〔Ｐ〕はα−リン
酸三カルンウム粉末単独もしくはＸ線造影性を必要とす
る場合それとヨードホルム粉末とからなっている。The powder [P] constituting the curable composition of the present invention consists of α-tricarunium phosphate powder alone or, if X-ray contrastability is required, it and iodoform powder.
前記α−リン酸三カルシウムは公知の方法で製造するこ
とが出来、たとえば次の方法により製造することができ
る。The α-tricalcium phosphate can be produced by a known method, for example, by the following method.
即ち、Ｔ−ピロリン酸カルシウムと炭酸力ルンウムとを
等モル量で均一に混合し、十分に乾燥させた後１０００
〜１４００℃、好ましくは１２５０℃前後で約１時間焼
成し、得られる生成物を微粉砕して粒径１００μｍ以下
の微粉末とすることによって得ることができる。他の方
法としては、リン酸水Ｎカルシウムニ水和物と炭酸カル
シウムを２対１のモル比で均一に混合した後、前記方法
とほぼ同一条件で焼成、粉砕して得ることもできる。That is, calcium T-pyrophosphate and carbonate are uniformly mixed in equimolar amounts, thoroughly dried, and then heated to 1000 ml.
It can be obtained by calcining at ~1400°C, preferably around 1250°C for about 1 hour, and pulverizing the resulting product into a fine powder with a particle size of 100 μm or less. Another method is to uniformly mix N-calcium phosphate dihydrate and calcium carbonate at a molar ratio of 2:1, and then sinter and crush the mixture under substantially the same conditions as the above method.
粉末の粒径は好ましくは２０μｍ以下である。The particle size of the powder is preferably 20 μm or less.
また、前記ヨードホルム粉末は、従来から通常この種の
用途に使用されているものが使用出来、該粉末の粒径は
、好ましくは１０μｍ以下である。Further, the iodoform powder that has been conventionally used for this type of application can be used, and the particle size of the powder is preferably 10 μm or less.
なお、ヨードホルム粉末の配合量は、α−リン酸三カル
シウム１００重量部に対し、５〜３０重量部、特に好ま
しくは１５〜２５重量部である。The amount of iodoform powder to be blended is 5 to 30 parts by weight, particularly preferably 15 to 25 parts by weight, per 100 parts by weight of α-tricalcium phosphate.
ヨードホルム粉末の配合量が前記範囲より少な過ぎると
硬化性組成物のＸ線造影性が不足してくるので好ましく
なく、一方過剰になると相対的にα−リン酸三カルシウ
ムが少なくなるため硬化性が悪くなるので好ましくない
。If the amount of iodoform powder blended is too small than the above range, the X-ray contrast properties of the curable composition will be insufficient, which is undesirable.On the other hand, if it is too much, the curability will decrease because the amount of α-tricalcium phosphate will be relatively small. I don't like it because it makes it worse.
本発明に使用する粉剤ＣＰ）は以上説明した通り、α−
リン酸三カルシウム粉末もしくはそれとヨードホルム粉
末からなっているが、さらに必要に応じ硫酸バリウム粉
末、塩基性炭酸ビスマス粉末、シリカ粉末、アルミナ粉
末、アパタイト粉末等を配合してもよい。As explained above, the powder CP used in the present invention is α-
It consists of tricalcium phosphate powder or tricalcium phosphate powder and iodoform powder, but barium sulfate powder, basic bismuth carbonate powder, silica powder, alumina powder, apatite powder, etc. may be further blended as necessary.
本発明の硬化性組成物を構成する硬化液〔Ｌ〕はリン酸
三アンモニウム、蓚酸アンモニウム、酢酸アンモニウム
及び酒石酸水素すｌ−ＩＪウムからなる群から選ばれた
少なくとも一種の塩の水溶液である。The curing liquid [L] constituting the curable composition of the present invention is an aqueous solution of at least one salt selected from the group consisting of triammonium phosphate, ammonium oxalate, ammonium acetate, and sulfur hydrogen tartrate.
これらの塩の水溶液濃度は、リン酸三アンモニウムが１
０〜４０重量％、好ましくは１０〜２０重量％；蓚酸ア
ンモニウムが３〜５重量％、好ましくは４〜５重量％；
酢酸アンモニウムが２０〜６０重量％、好ましくは３０
〜５０重量％；酒石酸水素す） ＩＪウムが３〜５重量
％、好ましくは４〜５重量％が適当である。水溶液濃度
が前記範囲より小さいと硬化性組成物の硬化性、作業性
が悪くなる傾向にある。一方、前記範囲より大きいと練
和硬化物の溶解性が大きくなる傾向にある。The concentration of these salts in aqueous solution is 1
0-40% by weight, preferably 10-20% by weight; 3-5% by weight of ammonium oxalate, preferably 4-5% by weight;
Ammonium acetate is 20-60% by weight, preferably 30%
~50% by weight; hydrogen tartrate) 3 to 5% by weight, preferably 4 to 5% by weight of IJum is suitable. If the concentration of the aqueous solution is lower than the above range, the curability and workability of the curable composition tend to deteriorate. On the other hand, if it is larger than the above range, the solubility of the kneaded and cured product tends to increase.
本発明にふいては、硬化液としてポリエチレングリコー
ノペポリプロピレングリコール等のポリアルキレングリ
コールの水溶液（水溶液濃度５〜１５重量％）を練和性
等をよくするために併用することも可能である。さらに
必要に応じ増粘剤、界面活性剤等の各種添加剤を少量添
加することも可能である。In the present invention, an aqueous solution (aqueous solution concentration of 5 to 15% by weight) of polyalkylene glycol such as polyethylene glycone polypropylene glycol can be used in combination as a curing liquid in order to improve kneading properties and the like. Furthermore, it is also possible to add small amounts of various additives such as thickeners and surfactants, if necessary.
本発明の硬化性組成物は以上説明した粉剤ＣＰ）と硬化
液ＣＬＩとからなり、それらを好ましくは〔Ｐ〕とＣＬ
）の重量比ＣＰ〕／ ＣＬ、］が１．０〜２．０となる
割合で、使用直前に練和し使用に供される。The curable composition of the present invention consists of the powder agent CP) and the curing liquid CLI as described above, preferably [P] and CL
) is kneaded and used immediately before use at a ratio such that the weight ratio CP]/CL,] is 1.0 to 2.0.
本発明の硬化性組成物は、化学的に歯の成分に近い、α
−リン酸三カルシウムを使用しているため生体適合性が
あり、また練和物のｐＨも中性付近にあり、生体に対す
る刺激性もなく、さらに崩壊率も小さい。それ故覆軍材
や根管充填材として好適であり、また覆軍材や根管充填
材として要求される練和物の適度な動粘性、操作性、硬
化性、封鎖性等の性状を満足しており、画期的な硬化性
組成物といえる。The curable composition of the present invention has α
- Since it uses tricalcium phosphate, it is biocompatible, and the pH of the kneaded product is near neutral, so it is not irritating to living organisms and has a low disintegration rate. Therefore, it is suitable as a covering material and root canal filling material, and also satisfies the properties such as appropriate kinematic viscosity, operability, hardening properties, and sealing properties of the kneaded material required for covering material and root canal filling material. It can be said to be a revolutionary curable composition.
以下、本発明を実施例により更に詳細に説明する。 Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例１〜６及び比較例１〜３
公知の方法によりγ−ピロリン酸カルシウムと炭酸カル
シウムを等モル混合し、焼成してα−リン酸三カルシウ
ムを合成し、粉砕して３００メツシユの篩を通過させて
、所定の粒度のα−リン酸三カルシウム粉末を得た。Examples 1 to 6 and Comparative Examples 1 to 3 γ-Calcium pyrophosphate and calcium carbonate were mixed in equimolar amounts by a known method, baked to synthesize α-tricalcium phosphate, and pulverized to pass through a 300-mesh sieve. In this way, α-tricalcium phosphate powder with a predetermined particle size was obtained.
このようにして得られたα−リン酸三カルシウム粉末（
α−ＴＣＰという）を使用して第１表に示す他の粉末成
分ＣＰ〕と混合し、ＪＩＳ−Ｔ６６０２の方法に準拠し
て第１表に示す硬化液〔Ｌ〕と練和した。（表中の数値
は重量部を示す。）かくして調製した練和物の崩壊率、
表面ｐＨ及びＸ線造影性を調べ、その結果を第１表下段
に示した。The α-tricalcium phosphate powder thus obtained (
α-TCP) was mixed with other powder components CP shown in Table 1 and kneaded with the hardening liquid [L] shown in Table 1 according to the method of JIS-T6602. (The numbers in the table indicate parts by weight.) The disintegration rate of the kneaded product thus prepared,
The surface pH and X-ray contrast property were investigated, and the results are shown in the lower part of Table 1.
第１表の試験結果より明らかの通り、本発明の硬化性組
成物は、硬化物の表面ｐＨが中性付近にあり、それ放生
体に対する刺激性がきわめて小さく、また崩壊率も小さ
く良好であった。As is clear from the test results in Table 1, the curable composition of the present invention has a surface pH of the cured product near neutrality, has very little irritation to the release body, and has a low disintegration rate. Ta.
一方、硬化液にリン酸三アンモニウム水溶液を使用した
比較例１およびポリアクリル酸ナトリウム水溶液を使用
した比較例２は崩壊率が高く、またポリアクリル酸水溶
液を使用した比較例３は硬化物の表面ｐＨが低く生体に
対する刺激性があり不適であった。On the other hand, Comparative Example 1, which used triammonium phosphate aqueous solution as the curing liquid, and Comparative Example 2, which used sodium polyacrylate aqueous solution, had a high disintegration rate, and Comparative Example 3, which used polyacrylic acid aqueous solution, had a high disintegration rate. The pH was low and irritating to living organisms, making it unsuitable.
注６）
分子旧約３０００の非イオン性ポリエチレングリコール
アクリル酸−イタコン酸共重合体（イタコン酸含有量３
５重量％）重合度２７００〜７５００
ＪＩＳ Ｔ−６６０２に準する。Note 6) Nonionic polyethylene glycol acrylic acid-itaconic acid copolymer with a molecular age of approx. 3000 (itaconic acid content 3
5% by weight) Degree of polymerization 2700-7500 According to JIS T-6602.
粉剤［Ｐ］と硬化液ＣＬ］とを１分間均一に練和し、該
練和物を容器に入れ、その表面を平らにして濾紙をのせ
、練和開始１５０秒後に水を滴下し、濾紙を湿らせ、密
封２４時間放置後、フラット型ｐＨ電極（ベックマン
フラット型複合電極＃３９５２３Ｓ−５０２Ａ）を濾紙
に接触させ練和物の表面ｐＨを測定した。Powder [P] and hardening liquid CL] were uniformly kneaded for 1 minute, the kneaded product was put into a container, the surface was flattened and a filter paper was placed on it, and 150 seconds after the start of kneading, water was added dropwise and the filter paper After moistening and sealing for 24 hours, use a flat pH electrode (Beckman
A flat type composite electrode #39523S-502A) was brought into contact with the filter paper to measure the surface pH of the kneaded product.
２ｍｍ厚の硬化物に８０ＫＶ、２００ｍへのＸ線を０．
０２秒間照射し、Ｘ線フィルムを感光させ調べた。A 2 mm thick cured product was exposed to X-rays at 80 KV and 200 m at 0.
The sample was irradiated for 02 seconds, and the X-ray film was exposed and examined.
Claims (2)
液とからなる組成物において、前記硬化液がリン酸二ア
ンモニウム、蓚酸アンモニウム、酢酸アンモニウム及び
酒石酸水素ナトリウムからなる群から選ばれた少なくと
も一種の塩の水溶液であることを特徴とする医科用また
は歯科用硬化性組成物。(1) A composition comprising a powder made of α-tricalcium phosphate powder and a hardening liquid, wherein the hardening liquid is at least one selected from the group consisting of diammonium phosphate, ammonium oxalate, ammonium acetate, and sodium hydrogen tartrate. A curable composition for medical or dental use, characterized in that it is an aqueous solution of a salt of.
ードホルム粉末５〜３０重量部からなる粉剤と硬化液と
からなる組成物において、前記硬化液がリン酸二アンモ
ニウム、蓚酸アンモニウム、酢酸アンモニウム及び酒石
酸水素ナトリウムからなる群から選ばれた少なくとも一
種の塩の水溶液であることを特徴とする医科用または歯
科用硬化性組成物。(2) A composition comprising a powder consisting of 100 parts by weight of α-tricalcium phosphate powder and 5 to 30 parts by weight of iodoform powder, and a curing liquid, wherein the curing liquid includes diammonium phosphate, ammonium oxalate, ammonium acetate, and tartaric acid. A curable composition for medical or dental use, which is an aqueous solution of at least one salt selected from the group consisting of sodium hydrogen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63218066A JP2609909B2 (en) | 1988-08-31 | 1988-08-31 | Medical or dental curable composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63218066A JP2609909B2 (en) | 1988-08-31 | 1988-08-31 | Medical or dental curable composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0265865A true JPH0265865A (en) | 1990-03-06 |
| JP2609909B2 JP2609909B2 (en) | 1997-05-14 |
Family
ID=16714116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63218066A Expired - Lifetime JP2609909B2 (en) | 1988-08-31 | 1988-08-31 | Medical or dental curable composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2609909B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007197329A (en) * | 2006-01-23 | 2007-08-09 | Kuraray Medical Inc | Calcium phosphate composition and method for producing the same |
| JP2012236854A (en) * | 2012-08-10 | 2012-12-06 | Kuraray Noritake Dental Inc | Method for producing calcium phosphate composition |
| JP2017145195A (en) * | 2016-02-15 | 2017-08-24 | 株式会社松風 | Two-paste type root canal-filling sealer composition |
| JP2017145196A (en) * | 2016-02-15 | 2017-08-24 | 株式会社松風 | Root canal-filling sealer composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5988351A (en) * | 1982-11-10 | 1984-05-22 | 科学技術庁無機材質研究所長 | Production of apatite cement hardened body |
| JPS62153204A (en) * | 1985-12-27 | 1987-07-08 | Advance Res & Dev Co Ltd | Root canal filling material for dental use |
| JPS62182146A (en) * | 1985-10-11 | 1987-08-10 | 三井東圧化学株式会社 | Hardenable material |
-
1988
- 1988-08-31 JP JP63218066A patent/JP2609909B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5988351A (en) * | 1982-11-10 | 1984-05-22 | 科学技術庁無機材質研究所長 | Production of apatite cement hardened body |
| JPS62182146A (en) * | 1985-10-11 | 1987-08-10 | 三井東圧化学株式会社 | Hardenable material |
| JPS62153204A (en) * | 1985-12-27 | 1987-07-08 | Advance Res & Dev Co Ltd | Root canal filling material for dental use |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007197329A (en) * | 2006-01-23 | 2007-08-09 | Kuraray Medical Inc | Calcium phosphate composition and method for producing the same |
| JP2012236854A (en) * | 2012-08-10 | 2012-12-06 | Kuraray Noritake Dental Inc | Method for producing calcium phosphate composition |
| JP2017145195A (en) * | 2016-02-15 | 2017-08-24 | 株式会社松風 | Two-paste type root canal-filling sealer composition |
| JP2017145196A (en) * | 2016-02-15 | 2017-08-24 | 株式会社松風 | Root canal-filling sealer composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2609909B2 (en) | 1997-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5061116B2 (en) | Bone repair material | |
| EP2421543B1 (en) | Dual-phase calcium phosphate cement composition | |
| JPH0645487B2 (en) | Curing material | |
| EP0538913B1 (en) | Hardening material for medical and dental use | |
| JPS6242625B2 (en) | ||
| GB2127033A (en) | Dental cement | |
| JPS6272363A (en) | Medical or dental cement composition | |
| JPH01208347A (en) | Curable composition | |
| JPH0265865A (en) | Medical or dental curable composition | |
| JPH10248915A (en) | Calcium phosphate cement curing solution and composition for calcium phosphate cement cured object | |
| Ishikawa et al. | Basic properties of apatite cement containing spherical tetracalcium phosphate made with plasma melting method | |
| JP2754245B2 (en) | Root canal filling material | |
| JP2742814B2 (en) | Root canal filling material | |
| JPH02311406A (en) | Root canal-filling material composition | |
| JPH0513901B2 (en) | ||
| JPH0585914A (en) | Curing type paste material | |
| JPS62153204A (en) | Root canal filling material for dental use | |
| JP3423951B2 (en) | Calcium phosphate hardened powder | |
| JPH0526503B2 (en) | ||
| JPH01301543A (en) | Curable composition | |
| JP4210359B2 (en) | Dental impression material composition | |
| WO1990008530A1 (en) | Root canal filling material comprising hardenable paste | |
| JPH0331470B2 (en) | ||
| JPH0228104A (en) | Root canal filler | |
| JPH07114804B2 (en) | Medical curable composition |